Efficacy and Safety of Toreforant, a Selective Histamine H4 Receptor Antagonist, for the Treatment of Moderate-to-Severe Plaque Psoriasis: Results from a Phase 2 Multicenter, Randomized, Double-blind, Placebo-controlled Trial.

CONCLUSIONS: Toreforant efficacy at 30 and 60 mg was greater than placebo but did not meet predefined success criterion. J Drugs Dermatol. 2018;17(8):873-879. PMID: 30124726 [PubMed - in process]

https://www.ncbi.nlm.nih.gov/pubmed/30124726?dopt=Abstract

Source: Journal of Drugs in Dermatology - August 22, 2018 Category: Dermatology Tags: J Drugs Dermatol Source Type: research